Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Vertex Pharmaceuticals got a healthy boost on Tuesday, with shares climbing nearly 3% thanks to a double dose of analyst ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% ...